Analytical Data
-
Gene name
NTRK1/TrkA-I
- Application
-
Alternative Names
MTC; TRK1; TRK-A; P140-TrkA; High Affinity Nerve Growth Factor Receptor; TRK1 Transforming Tyrosine Kinase Protein; Tropomyosin-related kinase A; Tyrosine kinase receptor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P04629
-
Expression Region
Val278~Asn386
-
Molecular Weight
16kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NTRK1 encodes the neurotrophic receptor TrkA, which is crucial for the development and maintenance of the nervous system. TrkA is a high-affinity receptor for nerve growth factor (NGF), playing a vital role in neuronal survival, differentiation, and growth. Aberrant activation of NTRK1 has been implicated in various cancers, including pediatric tumors such as neuroblastoma, as well as adult tumors. Research has shown that NTRK gene fusions, involving NTRK1 and other genes, can lead to constitutive activation of TrkA, promoting tumorigenesis. This has sparked interest in developing targeted therapies that can inhibit NTRK1 signaling. Recombinant TrkA-I protein is instrumental in studying these mechanisms, as it serves as a valuable tool for understanding ligand-receptor interactions, downstream signaling pathways, and the role of TrkA in cellular processes. Additionally, recombinant TrkA-I facilitates the identification and screening of potential therapeutic compounds, enabling the advancement of targeted treatments for NTRK1-related malignancies. The ongoing research endeavors surrounding NTRK1/TrkA-I highlight its significance not only in basic neuroscience but also in translational medicine, paving the way for innovative therapeutic strategies tailored to patients with NTRK gene alterations.
